Stevanato Group (NYSE:STVN) today announced a collaboration with Thermo Fisher Scientific (NYSE:TMO) on drug delivery technology.
The partnership aims to bring a fully integrated, on-body delivery system platform for subcutaneous administration to market.
Stevanato Group said in a news release that the planned device will be semi-reusable and provide micro-precision basal doses and full-content bolus injections. The company intends for the flexible, customizable platform to administer a wide range of therapies.
With Thermo Fisher, the collaboration enables the delivery of small molecules and biologics. These include large volumes delivered subcutaneously at home. The companies believe this could improve the adherence and effectiveness of pharmacological treatments.
What Stevanato Group and Thermo Fisher bring to this collaboration
In the partnership, Stevanato Group plans to provide pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment. Thermo Fisher is responsible for providing fill-finish and final assembly services. Together, they expect to offer pharmaceutical companies a cartridge-based, on-body delivery system.
“We are proud to be working with Thermo Fisher Scientific to bring to the market our on-body delivery system for patients,” said Steven Kaufman, VP for drug delivery systems at Stevanato Group. “Thanks to this collaboration with Thermo Fisher, Stevanato Group will be able to respond quickly to changes in customers’ needs, enabling them to scale up production according to commercial demand. The on-body delivery system increases the accessibility of in-home care and administered treatment options.”
Stevanato Group added that the system enhances its sustainability efforts. A reusable controller extends the product’s lifespan and reduces waste. Meanwhile, the disposable pod with a pre-filled, pre-loaded cartridge can reduce user error and wasted product.
“This collaboration with Stevanato Group is an example of how we are leveraging our world-class experience and reliability in fill finish and sterile development to deliver innovative solutions at scale,” said Leon Wyszkowski, president of pharma services commercial operations, Thermo Fisher Scientific. “In line with our mission to enable our customers to make the world healthier, cleaner and safer, we’ll significantly improve patients’ access and adherence to critical medicines.”